E-Nose: Diagnostic Tool for Pleural TB

NCT ID: NCT02765087

Last Updated: 2017-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the diagnostic utility of the device 'Electronic Nose' for Pleural TB, which is a Extra pulmonary TB form, compared with pleural biopsy, the current gold standard.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the study is to determine the diagnostic utility of the device 'Electronic Nose' for Pleural TB, which is a Extra pulmonary TB form.

The patient who qualified for the study, according to the inclusion criteria, after consenting, will be guided through and oriented survey for risk factors, then a complete physical exam, and after that, the patient will breathe for 5 minutes trough the device, which stores the patient information, that later will be download to a computer and will be send to the server's manufacturer company, in Netherlands.

During and after the use of the device, investigators determine the adverse effects of the intervention, according to the CTCEA.

Investigators use the pleural biopsy, which is the gold standard, to determine the diagnostic utility of the test. And, will compare the results with other tests currently perform as the regular diagnostic routine, such as Chest CT, adenosine deaminase value of pleural fluid and cytomorphologic \& cytochemistry of the pleural fluid.

Patient Registries will be keep in an electronic database, as well as handwriting history, with the backup copy in the records of the hospital in which the patient was admitted.

Auditories will be realised by the Ethics Committee in different time frames.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis, Pleural

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pleural TB

This group consist of patients with TB pleural effusion.

Intervention:

1. Inform Consent
2. Medical History
3. E-Nose Device
4. Chest CT
5. Cytomorphologic \& Cytochemistry of pleural Fluid.
6. Adenosine Deaminase value of pleural Fluid.

Group Type EXPERIMENTAL

Medical History

Intervention Type OTHER

Oriented Survey and complete physical exam.

E-Nose

Intervention Type DEVICE

Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA

Chest CT

Intervention Type OTHER

Pleural Fluid Analysis

Intervention Type OTHER

Cytomorphology Cytochemistry Adenosine Deaminase Value

Control

Patients with pleural effusion with different aetiologies than Tuberculosis.

Intervention:

1. Inform Consent
2. Medical History
3. E-Nose Device
4. Chest CT
5. Cytomorphologic \& Cytochemistry of pleural Fluid.
6. Adenosine Deaminase value of pleural Fluid.

Group Type ACTIVE_COMPARATOR

Medical History

Intervention Type OTHER

Oriented Survey and complete physical exam.

E-Nose

Intervention Type DEVICE

Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA

Chest CT

Intervention Type OTHER

Pleural Fluid Analysis

Intervention Type OTHER

Cytomorphology Cytochemistry Adenosine Deaminase Value

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medical History

Oriented Survey and complete physical exam.

Intervention Type OTHER

E-Nose

Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA

Intervention Type DEVICE

Chest CT

Intervention Type OTHER

Pleural Fluid Analysis

Cytomorphology Cytochemistry Adenosine Deaminase Value

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Accept to participate in the study through a signed informed consent approved by the Ethical Committee of our Institution.
2. More than 15 years old.
3. Pleural effusion of any etiology

Exclusion Criteria

1. Severe compromise of the general condition
2. Not capable to exhaled through the E-nose.
3. No possibility to follow-up.
4. By discretion of the research team.
Minimum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The ENose Company, Zutphen, Netherlands

UNKNOWN

Sponsor Role collaborator

Foundation for Research in Mycobacteria (FUNDAIM)

OTHER

Sponsor Role collaborator

Universidad Central de Venezuela

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jacobus H. de Waard

Chief of Tuberculosis Laboratory

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jacobuss de Waard, PhD.

Role: PRINCIPAL_INVESTIGATOR

Instituto de Biomedicina

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto de Biomedicina

Caracas, DC, Venezuela

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Venezuela

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sergio Poli, MD

Role: CONTACT

Phone: +584265172608

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sergio Poli, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EN002

Identifier Type: -

Identifier Source: org_study_id